Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Secondary hyperparathyroidism occurs when low vitamin D, low calcium, or reduced kidney function drive the parathyroid glands to overproduce PTH, and correcting that underlying trigger is what brings high PTH down. Restoring vitamin D levels, along with adequate calcium intake, often normalizes PTH within weeks to months, but dosing, the type of vitamin D used, and whether kidney disease is present all change the outcome, so there are several important factors to review below. Because vitamin D deficiency can mimic primary hyperparathyroidism, testing calcium, phosphate, 25-hydroxyvitamin D, and kidney function first is essential to avoid the wrong treatment. Early signs such as fatigue, bone or muscle aches, cramps, and tingling are easy to dismiss, which is why a free, instant, online symptom check is a smart first move to organize what you are experiencing in just a few minutes. It will not replace lab work or a diagnosis, but it can clarify how urgent your symptoms may be and give you sharper questions to bring to your do
Secondary hyperparathyroidism is a common condition in which your body secretes too much parathyroid hormone (PTH) in response to low vitamin D levels. You may have seen the phrase “High parathyroid hormone and low 25 hydroxyvitamin D” on lab reports. This guide explains, in straightforward terms, why that happens, how vitamin D helps, and what you can do next.
Parathyroid hormone (PTH) is produced by four small glands behind your thyroid. Its main job is to keep calcium levels in your blood within a narrow range. When calcium dips, PTH goes up to:
25-Hydroxyvitamin D (25(OH)D) is the storage form of vitamin D circulating in your blood. It tells us how much vitamin D you have available. Levels below 20 ng/mL are considered low, and many labs aim for 30 – 50 ng/mL.
When 25(OH)D is low, your gut absorbs less calcium. Blood calcium may drop slightly—even if it stays “normal” on lab tests—your body senses that drop and compensates by raising PTH. Over weeks to months, continuously elevated PTH leads to secondary hyperparathyroidism.
Key steps in this feedback loop:
Secondary hyperparathyroidism can be subtle, especially early on. You might not notice anything “wrong,” or you may have vague symptoms:
These symptoms overlap with other conditions. If you have them along with lab findings of high PTH and low 25(OH)D, further evaluation is needed.
Your doctor will typically order:
Lab patterns in secondary hyperparathyroidism:
In chronic kidney disease (CKD), phosphate can rise and further fuel PTH release. Your doctor may check urine calcium and phosphate, plus imaging if bone or kidney issues are suspected.
The cornerstone of treating secondary hyperparathyroidism is correcting low vitamin D. Vitamin D therapy helps by:
Forms of vitamin D you might encounter:
Typical dosing strategies:
Your doctor will recheck 25(OH)D and PTH after 8–12 weeks. If levels remain low or PTH is still high, dosing may be adjusted. It’s rare—but possible—to develop high calcium levels (hypercalcemia) if doses are too high, so monitoring is key.
Optimizing vitamin D and calcium intake goes beyond supplements. Simple steps can boost results:
Regular physical activity also helps maintain healthy bone density and muscle strength, reducing the risk of falls and fractures.
Once treatment starts, ongoing care includes:
In people with CKD, close coordination with a nephrologist ensures that phosphate binders or active vitamin D analogues are used correctly.
If you suspect you have secondary hyperparathyroidism—especially if you’ve seen “High parathyroid hormone and low 25 hydroxyvitamin D” on your labs—you don’t have to wait for a clinic visit to start gathering information. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to better understand your symptoms and the tests you may need.
Always discuss new or worsening symptoms with your doctor. If you experience any of the following—severe bone pain, muscle spasms, confusion, or signs of kidney stones—seek medical attention promptly.
The information above is based on current clinical guidelines and peer-reviewed studies. It’s meant to give you a clear picture of why vitamin D matters in controlling high PTH and how treatment works. However, every person’s situation is unique. Always speak to a doctor about any concerns, especially if you have symptoms that could be life threatening or serious.
By understanding the link between low 25-hydroxyvitamin D and high parathyroid hormone, and by following a monitored vitamin D regimen, you can often bring PTH levels back to normal—and protect your bone and overall health.
(References)
* Slatopolsky E, Berkoben M, Kelber J, Brown A, Delmez J. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl. 1992 Oct;38:S43-9. PMID: 1405381.
* Coburn JW, Henry DA. Renal osteodystrophy. Adv Intern Med. 1984;30:387-424. PMID: 6397042.
* Shoji T, Marumo F. [Renal osteodystrophy]. Nihon Rinsho. 1993 Apr;51(4):1011-6. PMID: 8483256.
* Delmez JA. Calcitriol and secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1993;13(2):95-7. PMID: 8494948.
* Beckerman P, Silver J. Vitamin D and the parathyroid. Am J Med Sci. 1999 Jun;317(6):363-9. doi: 10.1097/00000441-199906000-00003. PMID: 10372835.
* Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999 Dec;73:S14-9. doi: 10.1046/j.1523-1755.1999.07304.x. PMID: 10633458.
* Michels TC, Kelly KM. Parathyroid disorders. Am Fam Physician. 2013 Aug 15;88(4):249-57. PMID: 23944728.
* Jean G. [Improving secondary hyperparathyroidism treatment in Maghreb to get rid of brown tumors]. Nephrol Ther. 2016 Apr;12(2):67-70. doi: 10.1016/j.nephro.2015.11.004. Epub 2016 Jan 21. PMID: 26806195.
* Mizobuchi M, Ogata H, Koiwa F. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment. Ther Apher Dial. 2019 Aug;23(4):309-318. doi: 10.1111/1744-9987.12772. Epub 2018 Dec 18. PMID: 30411503.
* Magagnoli L, Ciceri P, Cozzolino M. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs. Expert Opin Investig Drugs. 2024 Aug;33(8):775-789. doi: 10.1080/13543784.2024.2369307. Epub 2024 Jun 19. PMID: 38881200.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.